Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
University of Pittsburgh
Sahlgrenska University Hospital
Washington University School of Medicine
UNICANCER
University of Maryland, College Park
DxTerity Diagnostics
Gene Surgery LLC
Shanghai Bovax Biotechnology Co., Ltd.
University of Maryland, College Park
Xencor, Inc.
National Institutes of Health Clinical Center (CC)
Xencor, Inc.
Institut de Cancérologie de Lorraine
AIDS Malignancy Consortium
Abramson Cancer Center at Penn Medicine
Boston Medical Center
University of Iowa
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
GlaxoSmithKline
Oryx GmbH & Co. KG
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
OHSU Knight Cancer Institute
Stanford University
City of Hope Medical Center
Emory University
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Trans Tasman Radiation Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center